Second Generation TKI before and after Stem Cell Transplant for CML Blast Crisis in the Era of Precision Medicine, Where Do We Go from There?

Abstract

Copyright: © 2017 Farhan S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Despite the great advances in Tyrosine Kinase Inhibitors (TKI) in treatment of Chronic Myeloid Leukemia (CML) and great improvement in patients quality of life, those who progress to blast crisis still have dismal outcome [1]. The pathogenesis and mechanisms of progression of CML from chronic phase to Advance Phase (AP) or Blast Crisis (BC), including genetic instability and centrosomal aberrations, is complex and still not fully understood [2]. Hence, consensus on an optimal treatment approach has not been achieved.